Immunohistochemical detection of fibroblast growth factor receptor 3 in human breast cancer: Correlation with clinicopathological/molecular parameters and prognosis

Pathobiology

Volumn 77, Issue 5, 2010, Pages 231-240

  Kuroso, Kazuko ^a   Imai, Yasuo ^a   Kobayashi, Masashi ^a   Yanagimoto, Kunio ^a   Suzuki, Tsukasa ^a   Kojima, Masato ^a   Ueda, Yoshihiko ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Breast cancer; Fibroblast growth factor receptor 3; Immunohistochemistry; Prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 3; PROGESTERONE RECEPTOR; PROTEIN P53;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER INVASION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CELL MEMBRANE; CELL NUCLEUS; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CORRELATIONAL STUDY; CYTOPLASM; EPITHELIUM CELL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MYOEPITHELIUM CELL; OVERALL SURVIVAL; PAPILLOMATOSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL MEMBRANE; CELL NUCLEUS; COHORT STUDIES; CYTOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PROGNOSIS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; TUMOR MARKERS, BIOLOGICAL;

EID: 78649812967     PISSN: 10152008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000314346     Document Type: Article

References (34)

1. Basilico C, Moscatelli D: The FGF family of growth factors and oncogenes. Adv Cancer Res 1992;59:115-265.
2. Friesel RE, Maciag T: Molecular mechanisms of angiogenesis: fibroblast growth factor signal transduction. FASEB J 1995;9:919-925.
3. Jaye M, Schlessinger J, Dionne CA: Fibroblast growth factor receptor tyrosine kinases: molecular analysis and signal transduction. Biochem Biophys Acta 1992;1135:185-199.
4. Johnson DE, Williams LT: Structural and functional diversity in the FGF receptor multigene family. Adv Cancer Res 1993;60:1-41.
5. Coutts JC, Gallagher JT: Receptors for fibroblast growth factors. Immunol Cell Biol 1995;73:584-589.
6. Perez-Castro AV, Wilson J, Altherr MR: Genomic organization of the human fibroblast growth factor receptor 3 (FGFR3) gene and comparative sequence analysis with the mouse Fgfr3 gene. Genomics 1997;41:10-16.
7. Wüchner C, Hilbert K, Zabel B, Winterpacht A: Human fibroblast growth factor receptor
8. gene (FGFR3): genomic sequence and primer set information for gene analysis. Hum Genet 1997;100:215-219.
9. Naski MC, Wang Q, Xu J, Ornitz DM: Graded activation of fibroblast growth factor receptor 3. by mutations causing achondroplasia and thanatophoric dysplasia. Nat Genet 1996;13:233-237.
10. Wilcox WR, Tavormina PL, Krakow D, Kitoh H, Lachman RS, Wasmuth JJ, Thompson LM, Rimoin DL: Molecular radiologic, and histopathologic correlations in thanatophoric dysplasia. Am J Med Genet 1998;78:274-281.
11. Colvin JS, Bohne BA, Harding GW, McEwen DG, Ornitz DM: Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. Nat Genet 1996;12:390-397.
12. Chellaiah AT, McEwen DG, Werner S, Xu J, Ornitz DM: Fibroblast growth factor receptor (FGFR) 3. Alternative splicing in immunoglobulinlike domain III creates a receptor highly specific for acidic FGF/FGF-1. J Biol Chem 1994;269:11620-11627.
13. Murgue B, Tsunekawa S, Rosenberg I, de-Beaumont M, Podolsky DK: Identification of a novel variant form of fibroblast growth factor receptor 3 (FGFR3 IIIb) in human colonic epithelium. Cancer Res 1994;54:5206-5211.
14. Sturla L-M, Merrick AE, Burchill SA: FGFR3IIIS: a novel soluble FGFR3 spliced variant that modulates growth is frequently expressed in tumour cells. Br J Cancer 2003;89:1276-1284.
15. Chesi M, Nardini E, Brents LA, Schrock E, Ried T, Kuehl WM, Bergsagel PL: Frequent translocation t (4; 14) (p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 1997;16:260-264.
16. Chesi M, Brents LA, Ely SA, Bais C, Robbiani DF, Mesri EA, Kuehl WM, Bergsagel PL: Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood 2001;97:729-736.
17. Cappellen D, de Oliveira C, Ricol D, de Medina S G D, Bourdin J, Sastre-Garau X, Chopin D, Thiery JP, Radvanyi F: Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 1999;23:18-20.
18. Jang JH, Shin KH, Park JG: Mutations in fibroblast growth factor receptor 2 and fibroblast growth receptor 3 genes associated with human gastric and colorectal cancers. Cancer Res 2001;61:3541-3543.
19. Wu R, Connoloy D, Ngelangel C, Bosch FX, Munoz N, Cho KR: Somatic mutations of fibroblast growth factor receptor 3 (FGFR3) are uncommon in carcinomas of the uterine cervix. Oncogene 2000;19:5543-5546.
20. Billerey C, Chopin D, Aubriot-Lorton MH, Ricol D, Van Rhijn B, Gil Diez de Medina S, Bralet MP, Lefrere-Belda MA, Lahaye JB, Abbou CC, Bonaventure J, Zafrani ES, van der Kwast T, Thiery JP, Radvanyi F: Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol 2001;158:1955-1959.
21. van Rhijn BW, Lurkin I, Radvanyi F, Kirkels WJ, van der Kwast TH, Zwarthoff EC: The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res 2001;61:1265-1268.
22. Hernandez S, Lopez-Knowles E, Lloreta J, Kogevinas M, Amorós A, Tardón A, Carrato A, Serra C, Malats N, Real FX: Prospective study of FGFR3 mutations as a prognostic factor in non-muscle invasive urothelial bladder carcinomas. J Clin Oncol 2006;24:3664-3671.
23. Matsumoto M, Ohtsuki Y, Ochi K, Seike Y, Iseda N, Sasaki T, Okada Y, Kurabayashi A, Furihata M: Fibroblast growth factor receptor 3. protein expression in urothelial carcinoma of the urinary bladder, exhibiting no association with low-grade and/or non-invasive lesions. Oncol Rep 2004;12:967-971.
24. Barbisan F, Santinelli A, Mazzucchelli R, Lopez-Beltran A, Cheng L, Scarpelli M, van der Kwast T, Montironi R: Strong immunohistochemical expression of fibroblast growth factor receptor 3, superficial staining pattern of cytokeratin 20, and low proliferative activity define those papillary urothelial neoplasms of low malignant potential that do not recur. Cancer 2008;112:636-644.
25. Mhawech-Fauceglia P, Cheney RT, Fischer G, Beck A, Herrmann FR: FGFR3 and p53 protein expression in patients with pTa and pT1 urothelial bladder cancer. Eur J Surg Oncol 2006;32:231-237.
26. Sibley K, Stern P, Knowles MA: Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumors. Oncogene 2001;20:4416-4418.
27. Zammit C, Barnard R, Gomm J, Coope R, Shousha S, Coombes C, Johnston C: Altered intracellular localization of fibroblast growth factor receptor 3 in human breast cancer. J Pathol 2001;194:27-34.
28. Japanese Breast Cancer Society: The General Rules for Clinical and Pathological Recording of Breast Cancer, ed 15. Tokyo, Kanehara, 2004, pp 11-39.
29. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM: REporting recommendations for tumor MARKer prognostic studies (REMARK). Eur J Cancer 2005;41:1690-1696. (Pubitemid 41132629)
30. Tsuda H: HER-2 (c-erbB-2) test update: present status and problems. Breast Cancer 2006;13:236-248.
31. Powers CJ, McLeskey SW, Wellstein A: Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 2000;7:165-197.
32. Yoshimura N, Sano H, Hashiramoto A, Yamada R, Nakajima H, Kondo M, Oka T: The expression and localization of fibroblast growth factor-1 (FGF-1) and FGF receptor-1 (FGFR-1) in human breast cancer. Clin Immunol Immunopathol 1998;89:28-34.
33. Johnston CL, Cox HC, Gomm JJ, Coombes RC: Fibroblast growth factor receptors (FGFRs) localize in different cellular compartments. A splice variant of FGFR-3 localizes to the nucleus. J Biol Chem 1995;270:30643-30650.
34. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ: Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007;18:1133-1144.